Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions

被引：15
|
作者：
Ambati, Srikanth R. [1 ]
Slotkin, Emily K. [1 ]
Chow-Maneval, Edna [2 ]
Basu, Ellen M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Ignyta, San Diego, CA USA
来源：
JCO PRECISION ONCOLOGY | 2018年 / 2卷
基金：
美国国家卫生研究院;
关键词：
LYMPHOMA KINASE ALK; CLINICAL-RESPONSE; PAN-TRK; INHIBITOR; SARCOMA;
D O I：
10.1200/PO.18.00095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
  • [41] THE PREVALENCE AND CLINICOPATHOLOGIC FEATURE OF ALK, ROS1 AND RET FUSIONS IN EAST ASIAN PATIENTS WITH LUNG ADENOCARCINOMA
    Cai, Weijing
    Zhou, Caicun
    Ren, Shengxiang
    Su, Chunxia
    Li, Xuefei
    Li, Wei
    Li, Shuai
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S660 - S660
  • [42] Identification of Known and Novel ALK, RET and ROS1 Gene Fusions Using Archer Targeted Sequencing Technology
    O'Reilly, C.
    Song, W.
    Shah, R. H.
    Won, H.
    Nafa, K.
    Arcila, M. E.
    Ladanyi, M.
    Cheng, D. T.
    Berger, M.
    Benayed, R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 752 - 752
  • [43] Psammoma Bodies in Lung Adenocarcinoma: Incidence and Association With ALK/ROS1/RET Fusions
    Li, Yuan
    Shen, Xuxia
    Wang, Rui
    Hu, Haichuan
    Chen, Haiquan
    Mukhopadhyay, Sanjay
    MODERN PATHOLOGY, 2015, 28 : 483A - 483A
  • [44] Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1
    Haimes, Josh D.
    Stewart, Colin J. R.
    Kudlow, Brian A.
    Culver, Brady P.
    Meng, Bo
    Koay, Eleanor
    Whitehouse, Ann
    Cope, Nichola
    Lee, Jen-Chieh
    Ng, Tony
    McCluggage, W. Glenn
    Lee, Cheng-Han
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (06) : 773 - 780
  • [45] Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report
    Tang, Li-Bo
    Peng, Ying-Long
    Yang, Xiao-Rong
    Li, Jia-Ting
    Lu, Chang
    Zheng, Mei-Mei
    Sun, Lu
    Yang, Zheng
    Yan, Li-Xu
    Deng, Yu
    Chen, Zhi-Hong
    Lv, Si-Di
    Zhou, Qing
    Xu, Chong-Rui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 631 - 638
  • [46] Psammoma Bodies in Lung Adenocarcinoma: Incidence and Association With ALK/ROS1/RET Fusions
    Li, Yuan
    Shen, Xuxia
    Wang, Rui
    Hu, Haichuan
    Chen, Haiquan
    Mukhopadhyay, Sanjay
    LABORATORY INVESTIGATION, 2015, 95 : 483A - 483A
  • [47] Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing
    Zhang, Chenlu
    Wang, Zhiming
    Zhuang, Rongyuan
    Guo, Xi
    Feng, Yi
    Shen, Feng
    Liu, Wenshuai
    Zhang, Yong
    Tong, Hanxing
    Sun, Wending
    Liu, Jun
    Wang, Guan
    Dai, Chun
    Lu, Weiqi
    Zhou, Yuhong
    ONCOTARGETS AND THERAPY, 2020, 13 : 10335 - 10342
  • [48] ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
    Aisner, Dara L.
    Nguyen, Teresa T.
    Paskulin, Diego D.
    Le, Anh T.
    Haney, Jerry
    Schulte, Nathan
    Chionh, Fiona
    Hardingham, Jenny
    Mariadason, John
    Tebbutt, Niall
    Doebele, Robert C.
    Weickhardt, Andrew J.
    Varella-Garcia, Marileila
    MOLECULAR CANCER RESEARCH, 2014, 12 (01) : 111 - 118
  • [49] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Liu, Dazhi
    Offin, Michael
    Harnicar, Stephen
    Li, Bob T.
    Drilon, Alexander
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
  • [50] External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay
    Kim, So-Woon
    Do, Sung-Im
    Na, Kiyong
    ANTICANCER RESEARCH, 2021, 41 (09) : 4609 - 4617
12345